JAAD Int
GLP-1 drugs linked to higher rates of hair loss, real-world data suggest
A real‑world multicenter TriNetX cohort study spanning 2014 to 2024 found significantly increased risk of nonscarring hair loss among GLP‑1 receptor agonist (RA) users compared with matched controls. Incidence curves diverged beginning around 2019, with GLP‑1 RA users showing higher rates of telogen effluvium (TE), androgenetic alopecia (AGA), and overall nonscarring hair loss (NSHL), particularly by 12 months (e.g., TE adjusted odds ratio [aOR], 1.76; AGA aOR, 1.64; NSHL aOR, 1.40). While the mechanisms remain unclear, investigators note that rapid weight loss, nutritional shifts, or medication‑specific effects may contribute to telogen effluvium in this population.
Clinical takeaway: When initiating GLP‑1 therapy, counsel patients about possible hair shedding and assess for nutritional deficiencies or rapid weight‑loss patterns if hair loss occurs.
Source:
Vidal SI, et al. (2026, February 9). JAAD Int. Increased Incidence and Risk of Hair Loss with GLP-1 Receptor Agonists: A Real-World Multicenter TrinetX Cohort Study. https://www.sciencedirect.com/science/article/pii/S2666328726000180